CMTM6 and melanoma: CMTM6 knockdown leads to decreased expression of PD-L1 in 12 human tumor lines of melanoma, thyroid cancer, colorectal cancer, lung cancer and CML, as well as in three short-term melanoma xenografts (Mezzadra et al., 2017).